San Diego – April 5, 2017 – Cooley advised Bellicum Pharmaceuticals on its $69 million public offering of 5,750,000 shares of common stock, including the exercise by the underwriters of their option to purchase up to 750,000 additional shares.
Citigroup and Jefferies acted as joint book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann, Raymond James and SunTrust Robinson Humphrey acted as co-managers.
Bellicum, which trades on The NASDAQ Global Market as “BLCM,” is a clinical-stage biopharmaceutical company focused on developing novel cellular immunotherapies for certain cancers and orphan inherited blood disorders.
In 2014, Cooley advised Bellicum on its $160 million initial public offering.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.